Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- TETRA Technologies (TTI) Tops Q3 EPS by 1c, Beats on Revenue
- Cabot Corp. (CBT) Tops Q4 EPS by 7c, Beats on Revenue; Offers FY EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
